Mediastinal lymphadenopathy on admission is associated with prognosis in COVID-19 patients: multicentre data on 410 patients

Correspondence

Francesco Sardanelli\textsuperscript{1,2}, MD, francesco.sardanelli@unimi.it ***
Andrea Cozzi\textsuperscript{2}, MD, andrea.cozzi1@unimi.it ***
Lorenzo Monfardini\textsuperscript{3}, MD, lore.monfa@gmail.com
Claudio Bnà\textsuperscript{3}, MD, claudio.bna@poliambulanza.it
Riccardo Alessandro Foà\textsuperscript{4}, MD, riccardo.foa@gmail.com
Angelo Spinazzola\textsuperscript{4}, MD, aspina@libero.it
Silvia Tresoldi\textsuperscript{5}, MD, silvia.3soldi@gmail.com
Maurizio Cariati\textsuperscript{4}, MD, maurizio.cariati@asst-santipaolocarlo.it
Francesco Secchi\textsuperscript{1,2}, MD, francesco.secchi@unimi.it
Simone Schiaffino\textsuperscript{1}, MD, schiaffino.simone@gmail.com

*** Francesco Sardanelli and Andrea Cozzi contributed equally to this letter

\textsuperscript{1} Unit of Radiology, IRCCS Policlinico San Donato, Via Rodolfo Morandi 30, 20097 San Donato Milanese, Italy.
\textsuperscript{2} Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Luigi Mangiagalli 31, 20133 Milano, Italy.
\textsuperscript{3} Unit of Interventional Radiology, Unit of Radiology, Fondazione Poliambulanza Istituto Ospedaliero, Via Leonida Bissolati 57, 25124 Brescia, Italy
\textsuperscript{4} Unit of Interventional Radiology, Unit of Radiology, ASST Crema - Ospedale Maggiore, Largo Ugo Dossena 2, 26013 Crema, Italy
5 Diagnostic and Interventional Radiology Service, ASST Santi Paolo e Carlo, Via Antonio di Rudini 8, 20142 Milano, Italy
Corresponding author

Prof. Francesco Sardanelli

Full Professor of Radiology, Università degli Studi di Milano

Director, Postgraduate School in Radiodiagnostics, Università degli Studi di Milano

Director, Unit of Radiology, IRCCS Policlinico San Donato

Via Morandi 30, 20097 San Donato Milanese, Milan, Italy

E-mail: francesco.sardanelli@unimi.it

Tel. +39 0252774626 (secretariat); +39 0252774637 (direct line); +39 3939149287 (mobile)
Xavier Valette and colleagues\(^1\) reported a high (60%) prevalence of mediastinal lymphadenopathy in 15 COVID-19 patients admitted to intensive care unit (ICU), an eleven-fold discrepancy with systematic reviews reporting pooled prevalence of 3·4\(^2\) and 5·4\(^3\). This topic deserves discussion, especially considering that limited sample sizes imply large confidence intervals.

We reviewed 410 COVID-19 patients (288 males, median age 68 years, IQR 57–78) who underwent CT at emergency department (ED) admission in three hospitals in Lombardy, Italy (Fondazione Poliambulanza Istituto Ospedaliero, Brescia; ASST Crema, Ospedale Maggiore, Crema; ASST Santi Paolo e Carlo, Ospedale San Paolo, Milano), from February 21 to March 18, 2020, during the pandemic peak. We found 76 patients with mediastinal lymphadenopathies greater than one cm, resulting into an 18·5% prevalence (95% CI 15%–22%).

Our CT examinations were performed at ED admission, while Valette’s data\(^1\) derive from ICU patients. Thus, our lower lymphadenopathy prevalence could be explained by a lower rate of patients requiring ICU admission during hospitalization (60/410, 15%). However, of these 60 patients, only 15 had lymphadenopathies at ED admission (25%, 95% CI 16%–36%)

Valette and colleagues\(^1\) hypothesized that disease severity could probably explain the discrepancy found between previous data and their ICU population. After applying the Bonferroni correction for multiple comparisons in our series of patients (obtaining a p value threshold of 0·003), we found no significant differences between patients with and without lymphadenopathies in terms of sex, age, oncological history, non-invasive ventilation or ICU admission during hospitalization, length of hospital stay, laboratory findings, and CT features such as parenchymal involvement and disease progression, both assessed according to the classification by Bernheim and colleagues\(^4\) (Table 1). However, lymphadenopathies at admission were significantly more frequent in patients which exhibited a crazy paving pattern at CT and in patients who died during hospitalization than in those discharged.

Despite invasive microbiological samples were not available for our patients (so we cannot exclude bacterial or fungal coinfections), our lymphadenopathy prevalence was lower than that reported by
Valette and colleagues\textsuperscript{1} but three-fold higher than those reported in other populations.\textsuperscript{2,3,5} We therefore agree in defining lymphadenopathy as a “not-atypical” feature of COVID-19. Furthermore, our data play in favour of considering lymphadenopathy as a predictor of worse outcome. The pathophysiological meaning of this finding in relation with host response to virus infection and the possibility to exploit this information in clinical management of COVID-19 patients remains to be investigated.
Table 1: Demographic, clinical, laboratory, and CT findings on admission

<table>
<thead>
<tr>
<th>Demographic and clinical findings</th>
<th>Patients with lymphadenopathies (n=76)</th>
<th>Patients without lymphadenopathies (n=334)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>59 M / 17 F</td>
<td>229 M / 105 F</td>
<td>0.119</td>
</tr>
<tr>
<td>Median age (years)</td>
<td>70 (IQR 63–79)</td>
<td>68 (IQR 56–78)</td>
<td>0.150</td>
</tr>
<tr>
<td>Any cancer history</td>
<td>3/36</td>
<td>25/289</td>
<td>0.949</td>
</tr>
<tr>
<td>Non-invasive ventilation during hospitalization</td>
<td>45/76</td>
<td>154/334</td>
<td>0.039</td>
</tr>
<tr>
<td>Intensive care unit admission during hospitalization</td>
<td>15/76</td>
<td>45/334</td>
<td>0.163</td>
</tr>
<tr>
<td>Median days of hospitalization</td>
<td>7 (IQR 5–13)</td>
<td>8 (4–14)</td>
<td>0.934</td>
</tr>
<tr>
<td>Death</td>
<td>37/76</td>
<td>99/334</td>
<td>0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratory findings</th>
<th>Patients with lymphadenopathies (n=76)</th>
<th>Patients without lymphadenopathies (n=334)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median $P_aO_2$ (%)</td>
<td>61 (IQR 49–70) a</td>
<td>63 (IQR 53–73) b</td>
<td>0.060</td>
</tr>
<tr>
<td>White blood cell count ($\times 10^3$ per µl)</td>
<td>7.9 (IQR 5.1–9.5) c</td>
<td>6.3 (IQR 4.7–8.8) d</td>
<td>0.132</td>
</tr>
<tr>
<td>Lymphocyte count ($\times 10^3$ per µl)</td>
<td>1.0 (IQR 0.7–1.3) c</td>
<td>1.0 (IQR 0.7–1.4) d</td>
<td>0.747</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CT features</th>
<th>Patients with lymphadenopathies (n=76)</th>
<th>Patients without lymphadenopathies (n=334)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median parenchymal involvement e</td>
<td>2 (IQR 1–3)</td>
<td>2 (IQR 1–2)</td>
<td>0.008</td>
</tr>
<tr>
<td>Median disease progression e</td>
<td>3 (IQR 2–3)</td>
<td>2 (IQR 2–3)</td>
<td>0.073</td>
</tr>
<tr>
<td>Bilateral lung involvement</td>
<td>71/76</td>
<td>314/334</td>
<td>0.846</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>9/76</td>
<td>18/334</td>
<td>0.041</td>
</tr>
<tr>
<td>Crazy paving pattern</td>
<td>33/76</td>
<td>73/334</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

All data were acquired on admission unless otherwise specified; p values were calculated with the Mann–Whitney $U$ test or the $\chi^2$ test, as appropriate.

a data available for 66 patients
b data available for 307 patients
c data available for 36 patients
d data available for 293 patients
e according to the classification by Bernheim and colleagues
References


Acknowledgements

This study was partially supported by Ricerca Corrente funding from Italian Ministry of Health to IRCCS Policlinico San Donato.

The funder was not involved by any means in any phase of the conceptualization, writing or publication of this manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit it for publication.

Authors’ contributions

Francesco Sardanelli and Andrea Cozzi: equal contribution in literature search, conceptualization, general project supervision, data collection, analysis, and interpretation, writing and revision of the manuscript.

Lorenzo Monfardini: data collection and project administration at Center 1 (Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy), writing and revision of the manuscript.

Claudio Bnà: data collection and project administration at Center 1 (Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy), writing and revision of the manuscript.

Riccardo Alessandro Foà: data collection and project administration at Center 2 (ASST Crema - Ospedale Maggiore di Crema, Crema, Italy), writing and revision of the manuscript.

Angelo Spinazzola: data collection and project administration at Center 2 (ASST Crema - Ospedale Maggiore di Crema, Crema, Italy), writing and revision of the manuscript.

Silvia Tresoldi: data collection and project administration at Center 3 (ASST Santi Paolo e Carlo, Milano, Italy), writing and revision of the manuscript.

Maurizio Cariati: data collection and project administration at Center 3 (ASST Santi Paolo e Carlo, Milano, Italy), writing and revision of the manuscript.

Francesco Secchi: data analysis and interpretation, general project administration, writing and revision of the manuscript.

Simone Schiaffino: data analysis and interpretation, general project administration, writing and revision of the manuscript.
All authors read and approved this submitted version of this manuscript.

Conflict of interest statements

A. Cozzi, L. Monfardini, C. Bnà, R.A. Foà, A. Spinazzola, S. Tresoldi, M. Cariati, and F. Secchi, all declare that they have no conflict of interest and that they have nothing to disclose.

S. Schiaffino declares to have received travel support from Bracco Imaging and to be member of speakers’ bureau for General Electric.

F. Sardanelli declares to have received grants from and to be member of speakers’ bureau/advisory board for Bayer, Bracco, and General Electric.